Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

Inclusion Criteria:

Diagnosis of PNH

Clinically Evident EVH defined by:

Anemia (Hgb ≤9.5 gram/deciliter) with absolute reticulocyte count ≥120 x 10^9/liter
Receiving an approved C5 inhibitor for at least 6 months prior to Day 1
Platelet count ≥30,000/microliters (µL)
Absolute neutrophil counts ≥500/μL
Documentation of/or willingness to receive vaccinations for N. meningiditis and prophylactic antibiotics as required

Exclusion Criteria:

History of a major organ transplant or hematopoietic stem cell transplantation (HSCT)
Participants with known aplastic anemia or other bone marrow failure that requires HSCT or other therapies including anti-thymocyte globulin and/or immunosuppressants
Known or suspected complement deficiency

Laboratory abnormalities at screening, including:

Alanine aminotransferase >2 x ULN (>3 x ULN in case of patients with documented liver iron overload defined by serum ferratin values

500 ng/ML)
Direct bilirubin >2 x ULN (unless due to EVH or documented Gilbert's Syndrome)
Current evidence of biliary cholestasis
Estimated glomerular filtration rate of <30 milliliters/minute/1.73 meter squared and/or are on dialysis
Evidence of human immunodeficiency virus, hepatitis B, or active hepatitis C infection at screening